AstraZeneca’s FluMist approval for self-administration could increase flu vaccine uptake: GlobalData
According to GlobalData, the US vaccination rate for seasonal influenza during the 2023-2024 season was estimated to be 47%, and this rate is only expected to increase marginally over the coming years.
And on 20 September, the US FDA approved AstraZeneca’s FluMist influenza nasal spray vaccine for self-administration.
AstraZeneca says FluMist has been shown to be as effective as other flu vaccines.When the FDA announced last year that it was reviewing the possibility of a self-administered flu vaccine ...
FluMist won't be available until next year, according to the website for FluMist, which is owned by AstraZeneca. Once ...
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback